Drug Database
Back to search

Belgium· BE-AMP-SAM575013-00

Oxlumo 94.5 mg/0.5 ml

A lumasiran product containing lumasiran sodium, registered in Belgium by Alnylam Netherlands. The same ATC class is registered in 12 of our 19 countries.

ATC A16AX18

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedOxlumo 94.5 mg/0.5 mlATCA16AX18REGISTER NO.BE-AMP-SAM575013-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lumasiran sodiumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lumasiran is registered in 12 of 19 countries.

Countries holding a registration under ATC A16AX18 (lumasiran), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose
Search lumasiran products by name

Lumasiran · ATC A16AX18

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Lumasiran Sodium
Manufacturer
Alnylam Netherlands
Country
Belgium (BE)
ATC code
A16AX18
ATC class
Lumasiran
Defined daily dose
2.3 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    7738016
  • be_apb
    4340105

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lumasiran in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lumasiran products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/10deb269-e313-47a3-b91a-b0f9722e3a98
GET /v1/drugs/10deb269-e313-47a3-b91a-b0f9722e3a98?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Oxlumo 94.5 mg/0.5 ml",
  "name_fr": "Oxlumo 94.5 mg/0.5 ml",
  "name_nl": "Oxlumo 94.5 mg/0.5 ml",
  "amp_code": "SAM575013-00",
  "strengths": [
    "189.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Lumasiran Sodium",
    "Lumasiran",
    "Sodium Hydroxide"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Lumasiran",
  "authorisation_numbers": [
    "EU/1/20/1496/001"
  ]
}
API referenceMCP serverPlans

See everything about lumasiran.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console